Amarin expands US operations
pharmafile | February 10, 2011 | News story | Sales and Marketing | AMR101, Amarin, Paul Huff, high cholesterol
Dublin-based biopharmaceutical company Amarin is to increase its US presence by setting up sales and marketing headquarters in New Jersey.
The planned facility will add to its existing research and development headquarters in Connecticut and the company has also appointed an experienced US marketer to its staff.
Paul Huff joins Amarin as chief commercial officer with a brief to drive the commercialisation of AMR101, the company’s phase III cholesterol treatment.
“Paul brings a wealth of industry knowledge and commercialisation experience to Amarin that will be invaluable as we seek to maximise the commercial value of AMR101,” said Amarin’s chief executive Joe Zakrzewski.
“Paul played a key role in the commercialisation of Lovaza and Niaspan, two of the most successful lipid products launched in the US market. He knows the lipid management markets well and will lead our efforts in preparing for the commercial launch of AMR101.”
Paul has over 25 years of cardiovascular-focused pharmaceutical marketing and sales experience, including as VP of Marketing at Reliant Pharmaceuticals, which markets Lovaza, the leading prescription Omega-3 product for reducing triglycerides.
He held a similar at Kos Pharmaceuticals, playing an integral role in the launch and commercialisation of its Niaspan, the leading prescription drug for raising HDL cholesterol.
Paul said: “Tens of millions of people have high triglycerides and, as such, heightened cardiovascular risk. Current therapies for treating this risk have limitations. I believe that AMR101 substantially overcomes these limitations and thus represents a new generation of triglyceride management.
“We believe that Amarin’s phase 3 MARINE trial results position AMR101 as potentially a best-in-class prescription drug for the treatment of patients with very high triglycerides, a large market opportunity as demonstrated by Lovaza sales of approximately $1 billion in the US alone,” he added.
Dominic Tyer
Related Content
Amarin gains positive opinion from Spanish Drug Pricing Committee for national reimbursement of Vazkepa in Spain
Amarin has announced that the Spanish Drug Pricing Committee has recommended the national reimbursement of …
EMA grants marketing authorisation for Amarin’s heart attack treatment
Amarin have been granted authorisation from the EMA to market a treatment that will reduce …
Label expansion of Amarin’s Vascepa has unanimous backing of FDA advisory panel
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has voted in favour of expanding …
